Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255
- From the Oklahoma State University Center for Health Services, Tulsa, Oklahoma
- Address correspondence to Jeffrey Stroup, Pharm.D., BCPS, Assistant Professor of Internal Medicine, Oklahoma State University Center for Health Sciences, 635 West 11th St., Tulsa, OK 74127. E-mail: jeffrey.stroup{at}okstate.edu
I read with interest the article by Boden et al. (1) regarding the prevention of fluid retention with the use of fenofibrate in combination with rosiglitazone. Impressive clinical data has recently been published on the use of thiazolidinedione (TZD) therapy for diabetes, but the increased incidence of edema and heart failure has been viewed as a major concern …
